Alnylam Sees FY24 Combined Net Product Revenues For AMVUTTRA, ONPATTRO, GIVLAARI And OXLUMO $1.4B-$1.5B
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals projects its FY24 combined net product revenues for AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO to be between $1.4 billion and $1.5 billion.
February 15, 2024 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals expects its FY24 combined net product revenues for AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO to reach $1.4B-$1.5B.
The projection of significant revenue growth for Alnylam Pharmaceuticals' key products directly impacts the company's financial outlook, likely leading to positive investor sentiment and potential stock price increase in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100